GH-axis pharmacology in healthy adults
Limited Human Evidence
Teichman et al. (2006) described prolonged GH and IGF-I secretion. The study was not a disease-outcome trial.
Also known as DAC:GRF, CJC-1295 with DAC, drug affinity complex GHRH analog
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
CJC-1295 is a growth hormone-releasing hormone analog modified for extended activity (often discussed with a drug-affinity complex, DAC). A 2006 healthy-adult study reported prolonged GH and IGF-I stimulation. That is pharmacology, not proof of a safe, effective treatment for a disease. It is not FDA-approved as a marketed GH-axis medicine in the way tesamorelin is.
CJC-1295 is a lab-made relative of GHRH designed to last longer in the bloodstream than native GHRH.
Online markets often sell 'with DAC' or 'without DAC' versions. Those informal products are not the same as a licensed drug.
Human data exist but are limited and not equivalent to a modern outcomes program.
CJC-1295 is built to act like growth hormone-releasing hormone: it can tell the pituitary to release growth hormone for a longer time than the natural hormone typically would.
As a GHRH receptor agonist with half-life extension (DAC albumin binding in the analog studied), CJC-1295 can increase GH pulse activity and circulating IGF-I. Tesamorelin is a related but distinct approved GHRH analog with a defined indication. Mechanistic similarity does not transfer approval or safety.
Step 1
Peptide
CJC-1295 (long-acting GHRH analog)
Step 2
Target
Pituitary GHRH receptor
Step 3
Pathway
GH secretion and IGF-I production
Step 4
Observed research effect
Prolonged GH/IGF-I increases in a healthy-adult PD study
Teichman et al. (2006) described prolonged GH and IGF-I secretion. The study was not a disease-outcome trial.
A 2006 Journal of Clinical Endocrinology & Metabolism study in healthy adults reported prolonged GH and IGF-I secretion after CJC-1295. This does not establish long-term safety or disease treatment.
GHRH-analog pharmacology is expected to raise GH. Compound-specific toxicology for unregulated products is not sufficiently established.
2006 · Human clinical trial
Population: Healthy adults in a pharmacokinetic/pharmacodynamic study
Objective: Characterize GH and IGF-I responses after administration of CJC-1295, a long-acting GHRH analog.
Main finding: The study reported prolonged stimulation of GH and IGF-I secretion after CJC-1295 in healthy adults. This is early human pharmacology, not an efficacy trial for a disease indication.
Limitations: Small, short-term healthy-volunteer design. Does not establish therapeutic benefit, long-term safety, or regulatory approval.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Limited human PD work is not a substitute for phase 3 safety and efficacy in a defined disease.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Clinical trial dosing (not a recommendation)
Doses used in published healthy-volunteer research are trial conditions, not a personal dosing recommendation.
Discovery
complete
Long-acting GHRH analog design including DAC chemistry.
Preclinical research
complete
GH-axis analog pharmacology.
Human studies
in progress · 2006
Healthy-adult GH/IGF-I study published.
Clinical trials
in progress
No approved indication established on this page.
Regulatory status
not started
Not established as an approved general GH therapy.
A long-acting GHRH analog studied for prolonged GH and IGF-I secretion. It is not an approved everyday medicine.
No. Both relate to GHRH signaling, but tesamorelin is an FDA-approved product for a specific HIV lipodystrophy indication. CJC-1295 is not that product.
Not established as an FDA-approved therapy for routine use.
Growth Hormone Research
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
View peptide →
Growth Hormone Research
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
View peptide →
Growth Hormone Research
Selective ghrelin-receptor GH secretagogue characterized mainly in experimental models. Not an approved medicine.
View peptide →